Impact of biologic therapy on functional status in patients with rheumatoid arthritis-a meta-analysis

Rheumatology (United Kingdom)

Volumn 52, Issue 12, 2013, Pages 2127-2135

  Callhoff, Johanna ^a   Weiß, Anja ^a   Zink, Angela ^a   Listing, Joachim ^a  

^a German Rheumatism Research Center   (Germany)

Author keywords

Biologic agents; DMARDs; Function; Meta analysis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NON BIOLOGIC DISEASE MODIFYING ANTI RHEUMATIC DRUG; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL THERAPY; DOUBLE BLIND PROCEDURE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS;

BIOLOGIC AGENTS; DMARDS; FUNCTION; META-ANALYSIS; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84887660544     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket266     Document Type: Article

References (50)

1. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
2. Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol 2012;39:54-9.
3. Wolfe F, Michaud K, Gefeller O et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
4. Westhoff G, Listing J, Zink A. Loss of physical independence in rheumatoid arthritis:interview data from a representative sample of patients in rheumatologic care. Arthritis Care Res 2000;13:11-22.
5. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-xiii.
6. Guyot P, Taylor P, Christensen R et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 2011;13:R204.
7. Schmitz S, Adams R, Walsh CD et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments:a Bayesian approach. Ann Rheum Dis 2012;71:225-30.
8. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
10. Kosinski M, Zhao SZ, Dedhiya S et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
11. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study:a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
12. Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis:the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
13. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial. Lancet 2004;363:675-81.
14. Singh JA, Christensen R, Wells GA et al. A network metaanalysis of randomized controlled trials of biologics for rheumatoid arthritis:a Cochrane overview. CMAJ 2009;181:787-96.
15. Lipsky PE, van der Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
16. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis:a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
17. Mandema JW, Salinger DH, Baumgartner SW et al. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 2011;90:828-35.
18. Guyot P, Taylor PC, Christensen R et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom. J Rheumatol 2012;39:1198-206.
19. Schoels M, Aletaha D, Smolen JS et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis:systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8.
20. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011;31:39-51.
21. Westhovens R, Robles M, Ximenes A et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
22. Bejarano V, Quinn M, Conaghan PG et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
23. Detert J, Bastian H, Listing J et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis:HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
24. Kavanaugh A, Fleischmann RM, Emery P et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis:26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
25. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET):a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
26. Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis:twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
27. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal:results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
28. Rigby W, Ferraccioli G, Greenwald M et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res 2011;63:711-20.
29. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
30. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis:a randomized trial. Ann Intern Med 2006;144:865-76.
31. Weinblatt M, Combe B, Covucci A et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs:a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16.
32. Takeuchi T, Matsubara T, Nitobe T et al. Phase II doseresponse study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol 2013;23:226-35.
33. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
34. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy:a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
35. Chen DY, Chou SJ, Hsieh TY et al. Randomized, doubleblind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc 2009;108:310-9.
36. Fleischmann R, Cutolo M, Genovese MC et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29.
37. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation:the CHANGE study. Mod Rheumatol 2008;18:252-62.
38. van de Putte LBA, Rau R, Breedveld FC et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis:a 12 week, phase II study. Ann Rheum Dis 2003;62:1168-77.
39. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial. Arthritis Rheum 2003;48:35-45.
40. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis:findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
41. Weinblatt ME, Fleischmann R, Huizinga TW et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis:results from the REALISTIC phase IIIb study. Rheumatology 2012;51:2204-14.
42. Combe B, Codreanu C, Fiocco U et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine:a double-blind comparison. Ann Rheum Dis 2006;65:1357-62.
43. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
44. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
45. Keystone E, Genovese MC, Klareskog L et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy:52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
46. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebocontrolled, phase III trial. Lancet 2009;374:210-21.
47. Tanaka Y, Harigai M, Takeuchi T et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis:results of the GO-FORTH study. Ann Rheum Dis 2012;71:817-24.
48. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
49. Keystone E, Burmester G, Furie R et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008;59:785-93.
50. Strand V, Balbir-Gurman A, Pavelka K et al. Sustained benefit in rheumatoid arthritis following one course of rituximab:improvements in physical function over 2 years. Rheumatology 2006;45:1505-13.